Comparison of Cryoballoon Vs. Pulsed Field Ablation in Patients with Symptomatic Paroxysmal Atrial Fibrillation (SINGLE SHOT CHAMPION): Study Protocol for a Randomized Controlled Trial

Overview

Journal Heart Rhythm O2

Date 2024 Aug 9

PMID 39119022

Authors

Jens Maurhofer

Thomas Kueffer

Sven Knecht

Gregor Thalmann

Patrick Badertscher

Nikola Kozhuharov

Philipp Krisai

Corinne Jufer

Salik Ur Rehman Iqbal

Dik Heg

Helge Servatius

Hildegard Tanner

Michael Kuhne

Laurent Roten

Christian Sticherling

Tobias Reichlin

Affiliations

Soon will be listed here.

Abstract

Background: Single-shot devices are increasingly used for pulmonary vein isolation (PVI) in atrial fibrillation (AF). The Arctic Front cryoballoon is the most frequently used single-shot technology. A recently developed novel pulsed field ablation (PFA) device (FARAPULSE) has been introduced with the aim to improve procedural safety and efficacy.

Objective: This study will compare the novel FARAPULSE PFA device and the Arctic Front cryoballoon for first PVI in patients with symptomatic paroxysmal AF.

Methods: SINGLE SHOT CHAMPION is a multicenter, randomized controlled trial with blinded endpoint adjudication by an independent clinical events committee. Overall, 210 patients with paroxysmal AF undergoing their PVI are randomized 1:1 between PFA and cryoballoon ablation. Continuous rhythm monitoring with an implantable cardiac monitor is performed in all patients.

Results: The primary endpoint is time to first recurrence of any atrial tachyarrhythmia (AF and/or organized atrial tachyarrhythmia) lasting ≥120 seconds and identified by the implantable cardiac monitor within 91 and 365 days postablation. The composite procedural safety endpoint includes cardiac tamponade requiring drainage, persistent phrenic nerve palsy, vascular complications requiring intervention, stroke/transient ischemic attack, atrioesophageal fistula, and death occurring during or up to 30 days after the procedure. Key secondary endpoints include (1) increase in high-sensitivity troponin on day 1 postablation, (2) analysis of postablation 3-dimensional electroanatomic mapping (first 25 patients per study group), (3) AF burden, and (4) quality-of-life changes.

Conclusion: SINGLE SHOT CHAMPION will evaluate the efficacy and safety of PVI using the novel FARAPULSE PFA for patients with symptomatic paroxysmal AF.

References

Turagam M, Neuzil P, Schmidt B, Reichlin T, Neven K, Metzner A . Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One-Year Outcomes From the MANIFEST-PF Registry. Circulation. 2023; 148(1):35-46. DOI: 10.1161/CIRCULATIONAHA.123.064959. View

Iliodromitis K, Lenarczyk R, Scherr D, Conte G, Farkowski M, Marin F . Patient selection, peri-procedural management, and ablation techniques for catheter ablation of atrial fibrillation: an EHRA survey. Europace. 2022; 25(2):667-675. PMC: 9935016. DOI: 10.1093/europace/euac236. View

Wazni O, Dandamudi G, Sood N, Hoyt R, Tyler J, Durrani S . Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation. N Engl J Med. 2020; 384(4):316-324. DOI: 10.1056/NEJMoa2029554. View

Charitos E, Ziegler P, Stierle U, Robinson D, Graf B, Sievers H . Atrial fibrillation burden estimates derived from intermittent rhythm monitoring are unreliable estimates of the true atrial fibrillation burden. Pacing Clin Electrophysiol. 2014; 37(9):1210-8. DOI: 10.1111/pace.12389. View

Servatius H, Kuffer T, Baldinger S, Asatryan B, Seiler J, Tanner H . Dexmedetomidine versus propofol for operator-directed nurse-administered procedural sedation during catheter ablation of atrial fibrillation: A randomized controlled study. Heart Rhythm. 2021; 19(5):691-700. DOI: 10.1016/j.hrthm.2021.12.028. View

Kuniss M, Pavlovic N, Velagic V, Hermida J, Healey S, Arena G . Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation. Europace. 2021; 23(7):1033-1041. PMC: 8286851. DOI: 10.1093/europace/euab029. View

Badertscher P, Weidlich S, Knecht S, Stauffer N, Krisai P, Voellmin G . Efficacy and safety of pulmonary vein isolation with pulsed field ablation vs. novel cryoballoon ablation system for atrial fibrillation. Europace. 2023; 25(12). PMC: 10751845. DOI: 10.1093/europace/euad329. View

Reddy V, Gerstenfeld E, Natale A, Whang W, Cuoco F, Patel C . Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2023; 389(18):1660-1671. DOI: 10.1056/NEJMoa2307291. View

Davalos R, Mir I, Rubinsky B . Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005; 33(2):223-31. DOI: 10.1007/s10439-005-8981-8. View

10.

Andrade J, Wells G, Deyell M, Bennett M, Essebag V, Champagne J . Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. N Engl J Med. 2020; 384(4):305-315. DOI: 10.1056/NEJMoa2029980. View

11.

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax J, Blomstrom-Lundqvist C . 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the.... Eur Heart J. 2020; 42(5):373-498. DOI: 10.1093/eurheartj/ehaa612. View

12.

Reddy V, Neuzil P, Koruth J, Petru J, Funosako M, Cochet H . Pulsed Field Ablation for Pulmonary Vein Isolation in Atrial Fibrillation. J Am Coll Cardiol. 2019; 74(3):315-326. DOI: 10.1016/j.jacc.2019.04.021. View

13.

Schmidt B, Bordignon S, Neven K, Reichlin T, Blaauw Y, Hansen J . EUropean real-world outcomes with Pulsed field ablatiOn in patients with symptomatic atRIAl fibrillation: lessons from the multi-centre EU-PORIA registry. Europace. 2023; 25(7). PMC: 10320231. DOI: 10.1093/europace/euad185. View

14.

Kuck K, Brugada J, Furnkranz A, Metzner A, Ouyang F, Chun K . Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2016; 374(23):2235-45. DOI: 10.1056/NEJMoa1602014. View

15.

Calkins H, Kuck K, Cappato R, Brugada J, Camm A, Chen S . 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. 2012; 14(4):528-606. DOI: 10.1093/europace/eus027. View

16.

Cheung C, Deyell M, Macle L, Verma A, Champagne J, Leong-Sit P . Repeat Atrial Fibrillation Ablation Procedures in the CIRCA-DOSE Study. Circ Arrhythm Electrophysiol. 2020; 13(9):e008480. DOI: 10.1161/CIRCEP.120.008480. View

17.

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

18.

Kuck K, Albenque J, Chun K, Furnkranz A, Busch M, Elvan A . Repeat Ablation for Atrial Fibrillation Recurrence Post Cryoballoon or Radiofrequency Ablation in the FIRE AND ICE Trial. Circ Arrhythm Electrophysiol. 2019; 12(6):e007247. DOI: 10.1161/CIRCEP.119.007247. View

19.

Calkins H, Hindricks G, Cappato R, Kim Y, Saad E, Aguinaga L . 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017; 14(10):e275-e444. PMC: 6019327. DOI: 10.1016/j.hrthm.2017.05.012. View

20.

Maurhofer J, Kueffer T, Knecht S, Madaffari A, Badertscher P, Seiler J . Comparison of the PolarX and the Arctic Front cryoballoon for pulmonary vein isolation in patients with symptomatic paroxysmal atrial fibrillation (COMPARE CRYO) - Study protocol for a randomized controlled trial. Contemp Clin Trials. 2023; 134:107341. DOI: 10.1016/j.cct.2023.107341. View